Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.9K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
The Ras Gene02:38

The Ras Gene

7.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
Mismatch Repair01:20

Mismatch Repair

7.0K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
7.0K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

6.3K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapy.

General thoracic and cardiovascular surgery·2026
Same author

Intratumoral heterogeneity of intermediate CLDN18.2 expression in gastric cancer.

International journal of clinical oncology·2026
Same author

ASO Visual Abstract: Preoperative Predictors of Surgical Complexity After Neoadjuvant Immunochemotherapy in Non-Small-Cell Lung Cancer.

Annals of surgical oncology·2026
Same author

Preoperative Predictors of Surgical Complexity After Neoadjuvant Immunochemotherapy in Non-small-cell Lung Cancer.

Annals of surgical oncology·2026
Same author

Core Temperature Estimation Using Wearable Earbud-Type Thermometer and Machine Learning During Light-Intensity Cycling Under Varying Indoor Ambient Temperatures.

Scandinavian journal of medicine & science in sports·2026
Same author

Calendar Calculation Savant Syndrome in Autism Spectrum Disorder: Cognitive Function Measured by the Wechsler Intelligence Scale.

Journal of autism and developmental disorders·2026

Related Experiment Video

Updated: Apr 5, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage

Kenichi Suda1, Kazuko Sakai2, Masaoki Ito3

  • 1Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Sakai, Japan; Department of Thoracic Surgery, Izumi City General Hospital, Izumi, Japan.

Clinical Lung Cancer
|April 4, 2026
PubMed
Summary

RNA-binding motif 10 (RBM10) mutations are common in non-small-cell lung cancer (NSCLC) with EGFR mutations, particularly in Japanese patients. These RBM10 mutations are linked to slower tumor growth and later onset.

Keywords:
Epidermal growth factor receptor (EGFR) mutationKRAS mutationMDM2 gene amplificationPersonalized treatmentRNA-binding motif protein 10 (RBM10)TP53 mutation

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Related Experiment Videos

Last Updated: Apr 5, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • RNA-binding motif 10 (RBM10) mutations in non-small-cell lung cancer (NSCLC) correlate with reduced sensitivity to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors.
  • The prevalence of RBM10 mutations in early-stage NSCLC and their associations with other genetic alterations remain largely uncharacterized.

Purpose of the Study:

  • To investigate the incidence and clinical significance of RBM10 mutations in surgically resected NSCLC.
  • To explore the relationship between RBM10 mutations and other common driver mutations, including EGFR and KRAS.

Main Methods:

  • Analysis of clinical and whole-exome sequencing genomic data from 190 NSCLC patients undergoing surgical resection.
  • Prospective, multicenter observational study design.
  • Statistical analysis to determine mutation frequencies and associations.

Main Results:

  • RBM10 mutations were identified in 11% of nonsquamous NSCLC cases but not in squamous cell carcinomas.
  • Higher incidences of RBM10 mutations were observed in tumors with EGFR (21%) and KRAS (12%) mutations compared to those without.
  • In EGFR-mutated tumors, RBM10 mutations were associated with older age, ground-glass opacity, and lower histological grade, suggesting indolent growth patterns.

Conclusions:

  • RBM10 mutations are frequent in Japanese NSCLC patients with EGFR mutations, especially L858R or uncommon variants.
  • RBM10 mutations are associated with clinical features indicative of indolent tumor behavior and late-onset disease.